NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

疫苗市場:按技術,用途,最終用途分類:全球機會分析和行業預測(2020-2027年)

Vaccine Market By Technology, Indication, and End Use : Global Opportunity Analysis and Industry Forecast, 2020-2027

出版商 Allied Market Research 商品編碼 980718
出版日期 內容資訊 英文 294 Pages
商品交期: 2-3個工作天內
價格
疫苗市場:按技術,用途,最終用途分類:全球機會分析和行業預測(2020-2027年) Vaccine Market By Technology, Indication, and End Use : Global Opportunity Analysis and Industry Forecast, 2020-2027
出版日期: 2020年11月20日內容資訊: 英文 294 Pages
簡介

2019年全球疫苗市場為324.63億美元。從2020年到2027年,該市場的複合年增長率預計為6.6%,到2027年將達到541.68億美元。

疫苗是用於為患者創造後天免疫力的生物製劑。接種疫苗有助於增強針對特定病原體的免疫反應。免疫在維持不同國家人民的健康方面起著重要作用。因此,它們被用於不同國家的疾病預防策略中。由於病毒和細菌感染的爆發,過去幾年對疫苗的需求增加了。疫苗主要提供給不同年齡的人們,可以改善他們的終生免疫系統,並可以預防各種形式的感染。

隨著國家免疫計劃在全球多個國家的普及,預計疫苗市場在預測期內將經歷顯著的市場增長。此外,一些國家爆發的肺炎球菌性腦膜炎激增導致對腦膜炎疫苗的需求激增,進一步推動了市場增長。但是,由於批准了新疫苗,政府對某些產品召回採取了嚴格的法規,污染預計將阻礙市場增長。相反,新興市場的高人口基數和全球醫療費用的增加為腦膜炎疫苗市場提供了巨大的增長機會。

按地區劃分,市場分為北美,歐洲,亞太地區和LAMEA。北美將在2019年擁有最大的市場份額,並有望在整個預測期內保持其優勢。這是由於諸如設備齊全,資金充足的醫院和診所,疫苗產品的大量採用以及先進的醫療基礎設施等因素造成的。此外,美國對疫苗接種意識很高,使其成為頂級市場公司的目標地區。但是,由於醫療設施的改善,可支配收入的增加以及經濟條件的迅速發展,亞太地區有望成為一個具有最大增長潛力的獲利地區。

該報告調查了疫苗市場,並提供了市場概況以及按技術,適應症,最終用途,地區和進入市場的公司概況的趨勢。

目錄

第1章簡介

第2章執行摘要

第3章市場概述

  • 市場定義和範圍
    • 2019年的關鍵成功策略
  • 頂級PLAYER排名
    • 主要投資口袋
  • 塑造疫苗行業/市場的關鍵力量
  • 市場動態
    • 促進因素
      • 傳染病患病率上升
      • 全球疫苗接種計劃迅速增加
      • 增加研發活動以開發新疫苗
    • 抑制因素
      • 疫苗生產需要更長的時間表
      • 與疫苗開發相關的高成本
    • 市場機會
      • 新興市場的增長機會
      • 醫療費用增加
    • 影響分析
  • 分析COVID-19對疫苗市場的影響
    • 概述
    • 影響分析

第4章疫苗市場:按技術

  • 概述
    • 市場規模和預測
  • 重組和結合疫苗
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 滅活□□疫苗
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 減毒活疫苗
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 類毒素疫苗
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 其他疫苗
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家

第5章全球疫苗市場:按指示

  • 概述
    • 市場規模和預測
  • 肺炎球菌感染
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 流感
    • 主要市場趨勢,增長因素和機遇
    • `市場規模和預測:按地區
    • 市場分析:按國家
  • 人乳頭瘤病毒
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 腦膜炎真菌病
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 輪狀病毒
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 痰,麻疹,腮腺炎,風疹(MMR)
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 白喉,百日咳,破傷風(DPT)
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 脊髓灰質炎
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 肝炎
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 其他適應症
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家

第6章疫苗市場:按最終用戶分類

  • 概述
    • 市場規模和預測
  • 小兒疫苗
    • 市場規模和預測
    • 市場分析:按國家
  • 成人疫苗
    • 市場規模和預測
    • 市場分析:按國家
  • 旅行者疫苗
    • 市場規模和預測
    • 市場分析:按國家

第7章全球疫苗市場:按地區

  • 概述
    • 市場規模和預測
  • 北美
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按國家
    • 市場規模和預測:按技術
    • 市場規模和預測:通過適應
    • 市場規模和預測:最終用戶
      • 美國市場規模和預測:按技術
      • 市場規模和預測:通過適應
      • 市場規模和預測:最終用戶
      • 墨西哥市場規模和預測:按技術
      • 墨西哥市場規模和預測:通過適應
      • 墨西哥市場規模和預測:按最終用戶劃分
      • 加拿大市場規模和預測:按技術
      • 加拿大市場規模和預測:通過適應
      • 加拿大市場規模和預測:最終用戶
  • 歐洲
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按國家
    • 市場規模和預測:按技術
    • 市場規模和預測:通過適應
    • 市場規模和預測:最終用戶
      • 德國市場規模和預測:按技術
      • 德國市場規模和預測:通過適應
      • 德國市場規模和預測:按最終用戶劃分
      • 法國市場規模和預測:按技術
      • 法國市場規模和預測:通過適應
      • 法國市場規模和預測:按最終用戶劃分
      • 英國市場規模和預測:按技術
      • 英國市場規模和預測:通過適應
      • 英國市場規模和預測:按最終用戶劃分
      • 意大利市場規模和預測:按技術
      • 意大利市場規模和預測:通過適應
      • 意大利市場規模和預測:按最終用戶劃分
      • 西班牙市場規模和預測:按技術
      • 西班牙市場規模和預測:通過適應
      • 西班牙市場規模和預測:最終用戶
      • 其他歐洲市場規模和預測:按技術
      • 其他歐洲市場規模和預測:通過適應
      • 其他歐洲市場規模和預測:按最終用戶劃分
  • 亞太地區
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按國家
    • 市場規模和預測:按技術
    • 市場規模和預測:通過適應
    • 市場規模和預測:最終用戶
      • 日本市場規模和預測:按技術
      • 日本市場規模和預測:通過適應
      • 日本市場規模和預測:按最終用戶劃分
      • 中國市場規模和預測:按技術
      • 中國市場規模和預測:通過適應
      • 中國市場規模和預測:按最終用戶劃分
      • 印度市場規模和預測:按技術
      • 印度市場規模和預測:通過適應
      • 印度市場規模和預測:按最終用戶劃分
      • 澳大利亞市場規模和預測:按技術
      • 澳大利亞市場規模和預測:通過適應
      • 澳大利亞市場規模和預測:按最終用戶劃分
      • 其他亞太市場規模和預測:按技術
      • 其他亞太市場規模和預測:通過適應
      • 其他亞太市場規模和預測:按最終用戶劃分
  • 拉美
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按國家
    • 市場規模和預測:按技術
    • 市場規模和預測:通過適應
    • 市場規模和預測:最終用戶
      • 巴西市場規模和預測:按技術
      • 巴西市場規模和預測:通過適應
      • 巴西市場規模和預測:按最終用戶劃分
      • 沙特阿拉伯市場規模和預測:按技術
      • 沙特阿拉伯市場規模和預測:通過適應
      • 沙特阿拉伯市場規模和預測:最終用戶
      • 南非市場規模和預測:按技術
      • 南非市場規模和預測:通過適應
      • 南非市場規模和預測:按最終用戶劃分
      • LAMEA剩餘市場規模和預測:按技術
      • LAMEA剩餘市場規模和預測:通過適應
      • LAMEA剩餘市場規模和預測:按最終用戶劃分

第8章公司簡介

  • AstraZeneca plc.
  • CSL Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc.
  • Johnson & Johnson
  • MERCK & CO. INC.
  • NOVAVAX, INC.
  • PFIZER INC.
  • Sanofi S.A.
  • SERUM INSTITUTE OF INDIA PVT. LTD
目錄
Product Code: A00168

Title:
Vaccine Market By Technology (Conjugate Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, and Other Vaccines), Indication (Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rotavirus, Varicella, Diphtheria, Pertussis, & Tetanus {DPT}, Polio, Hepatitis, Measles, Mumps, & Rubella {MMR}, and Other Indications), and End Use (Pediatric Vaccines, Adult Vaccines, and Traveler Vaccines): Global Opportunity Analysis and Industry Forecast, 2020-2027.

The global vaccine market accounted for $32,463 million in 2019 and is expected to reach $54,168 million by 2027, registering a CAGR of 6.6% from 2020 to 2027.

Vaccine is a biological preparation that is administered to produce acquired immunity in patients. Administration of vaccines aids to enhance the immune response against a specific pathogen. Vaccinations play a key role in sustaining people's health across different countries; hence, they are used in various national disease-prevention strategies. Due to the increased occurrence of both viral and bacterial infectious diseases, the demand for vaccines has grown over the past few years. Vaccinations are primarily provided to people of different ages, improving their immune system during their lives and ensuring defense against various forms of infectious diseases.

It is estimated that vaccine market is expected to experience significant market growth during the forecast period as there has been an increase in adoption in several countries across the globe by national immunization programs. In addition, surge in pneumococcal, meningococcal disease outbreaks in several countries has led to upsurge in demand for meningococcal vaccines, which further facilitate the growth of the market. However, stringent government regulations for the approval of new vaccines and recall of several products due to contamination are expected to impede the market growth. In contrast, high population base in emerging markets and global increase in healthcare spending provides significant growth opportunities for the meningococcal vaccine market.

Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest market share in 2019, and is expected to retain its dominance throughout the forecast period. This is attributed to factors such as well-equipped & better financed hospitals & clinics, high adoption rate for vaccine products, and sophisticated healthcare infrastructure. Moreover, the U.S. is the target area for top players in the market, owing to high awareness about vaccination. However, Asia-Pacific is expected to emerge as a lucrative area with maximum growth potential due to improvement in healthcare facilities, available disposable income, and rapidly developing economic conditions.

The global vaccine market is segmented on the basis of technology, indication, end user, and region. Depending on technology, the market is classified into recombinant & conjugate vaccines, live attenuated vaccines, inactivated vaccines, toxoid vaccines, and others. By indication, the market is classified into pneumococcal disease, influenza, human papilloma virus, meningococcal disease, rotavirus, varicella; diphtheria, pertussis, & tetanus (DPT), polio, hepatitis, measles; mumps, & rubella (MMR), and other indications. According to end user, the market is segmented into pediatric, adults, and travelers. By region, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, the UK, France, Spain, Italy, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The key players operating in the vaccine market include Serum Institute of India Pvt. Ltd., Pfizer, Johnson & Johnson, AstraZenecea, GlaxoSmithKline plc, Sanofi Aventis, Merck & Co., Inc., Emergent BioSolutions Inc., CSL Limited, Novavax, Inc.

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.

It offers a quantitative analysis from 2019 to 2027, which is expected to enable stakeholders to capitalize on prevailing market opportunities.

A comprehensive analysis of the countries in Latin America is provided to determine the existing opportunities.

The key market players and their strategies have been analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Technology type

  • Recombinant & Conjugate Vaccines
  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Toxoid Vaccines
  • Others

By Indication

  • Pneumococcal Disease
  • Influenza
  • Human Papilloma Virus
  • Meningococcal Disease
  • Rotavirus
  • Varicella, Measles, Mumps, & Rubella
  • Diphtheria, Pertussis, & Tetanus {DPT}
  • Polio
  • Hepatitis
  • Other Indications

By End User

  • Pediatric
  • Adults
  • Travelers

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

  • AstraZenecea
  • CSL Limited
  • Emergent BioSolutions Inc.
  • GSK
  • "Johnson &
  • Johnson"
  • Merck & Co., Inc.
  • Novartis
  • Novavax, Inc.
  • Pfizer
  • Sanofi Aventis
  • Serum Institute of India Ltd

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
    • 1.2.1.List of key players profiled in the report
  • 1.3.Research methodology
    • 1.3.1.Primary research
    • 1.3.2.Secondary research
    • 1.3.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
    • 3.1.1.Top winning strategies, 2019
  • 3.2.Top player positioning
    • 3.2.1.Top investment pockets
  • 3.3.Key forces shaping vaccine industry/market
  • 3.4.Market dynamics
    • 3.4.1.Drivers
      • 3.4.1.1.Increase in prevalence of infectious diseases
      • 3.4.1.2.Surge in immunization programs across the globe
      • 3.4.1.3.Increase in R&D activities to develop new vaccine
    • 3.4.2.Restraint
      • 3.4.2.1.Longer timelines required for vaccine production
      • 3.4.2.2.High cost associated with the development of vaccine
    • 3.4.3.Opportunity
      • 3.4.3.1.Growth opportunities in the emerging markets
      • 3.4.3.2.Increase in healthcare spending
    • 3.4.4.Impact Analysis
  • 3.1.COVID-19 impact analysis on vaccine market
    • 3.1.1.Overview
    • 3.1.2.Impact analysis

CHAPTER 4:VACCINE MARKET, BY TECHNOLOGY

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Recombinant & conjugate vaccine
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
  • 4.3.Inactivated vaccines
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by region
    • 4.3.3.Market analysis, by country
  • 4.4.Live attenuated vaccines
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast, by region
    • 4.4.3.Market analysis, by country
  • 4.5.Toxoid vaccines
    • 4.5.1.Key market trends, growth factors, and opportunities
    • 4.5.2.Market size and forecast, by region
    • 4.5.3.Market analysis, by country
  • 4.6.Other vaccines
    • 4.6.1.Key market trends, growth factors, and opportunities
    • 4.6.2.Market size and forecast, by region
    • 4.6.3.Market analysis, by country

CHAPTER 5:GLOBAL VACCINE MARKET, BY INDICATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Pneumococcal disease
    • 5.2.1.Key market trends, growth factors, and opportunities
    • 5.2.2.Market size and forecast, by region
    • 5.2.3.Market analysis, by country
  • 5.3.Influenza
    • 5.3.1.Key market trends, growth factors, and opportunities
    • 5.3.2.`Market size and forecast, by region
    • 5.3.3.Market analysis, by country
  • 5.4.Human papilloma virus
    • 5.4.1.Key market trends, growth factors, and opportunities
    • 5.4.2.Market size and forecast, by region
    • 5.4.3.Market analysis, by country
  • 5.5.Meningococcal disease
    • 5.5.1.Key market trends, growth factors, and opportunities
    • 5.5.2.Market size and forecast, by region
    • 5.5.3.Market analysis, by country
  • 5.6.Rotavirus
    • 5.6.1.Key market trends, growth factors, and opportunities
    • 5.6.2.Market size and forecast, by region
    • 5.6.3.Market analysis, by country
  • 5.7.Varicella, measles, mumps, and rubella (MMR)
    • 5.7.1.Key market trends, growth factors, and opportunities
    • 5.7.2.Market size and forecast, by region
    • 5.7.3.Market analysis, by country
  • 5.8.Diptheria, pertussis, and tetanus (DPT)
    • 5.8.1.Key market trends, growth factors, and opportunities
    • 5.8.2.Market size and forecast, by region
    • 5.8.3.Market analysis, by country
  • 5.9.Polio
    • 5.9.1.Key market trends, growth factors, and opportunities
    • 5.9.2.Market size and forecast, by region
    • 5.9.3.Market analysis, by country
  • 5.10.Hepatitis
    • 5.10.1.Key market trends, growth factors, and opportunities
    • 5.10.2.Market size and forecast, by region
    • 5.10.3.Market analysis, by country
  • 5.11.Other indications
    • 5.11.1.Key market trends, growth factors, and opportunities
    • 5.11.2.Market size and forecast, by region
    • 5.11.3.Market analysis, by country

CHAPTER 6:VACCINES MARKET, BY END USER

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Pediatric vaccines
    • 6.2.1.Market size and forecast
    • 6.2.2.Market analysis, by country
  • 6.3.Adult vaccines
    • 6.3.1.Market size and forecast
    • 6.3.2.Market analysis, by country
  • 6.4.Travelers vaccines
    • 6.4.1.Market size and forecast
    • 6.4.2.Market analysis, by country

CHAPTER 7:GLOBAL VACCINE MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends, growth factors, and opportunities
    • 7.2.2.Market size and forecast, by country
    • 7.2.3.Market size and forecast, by technology
    • 7.2.4.Market size and forecast, by indication
    • 7.2.5.Market size and forecast, by end user
      • 7.2.5.1.U.S. market size and forecast, by technology
      • 7.2.5.2.Market size and forecast, by indication
      • 7.2.5.3.Market size and forecast, by end user
      • 7.2.5.4.Mexico market size and forecast, by technology
      • 7.2.5.5.Mexico market size and forecast, by indication
      • 7.2.5.6.Mexico market size and forecast, by end user
      • 7.2.5.7.Canada market size and forecast, by technology
      • 7.2.5.8.Canada market size and forecast, by indication
      • 7.2.5.9.Canada market size and forecast, by end user
  • 7.3.Europe
    • 7.3.1.Key market trends, growth factors, and opportunities
    • 7.3.2.Market size and forecast, by country
    • 7.3.3.Market size and forecast, by technology
    • 7.3.4.Market size and forecast, by indication
    • 7.3.5.Market size and forecast, by end user
      • 7.3.5.1.Germany market size and forecast, by technology
      • 7.3.5.2.Germany market size and forecast, by indication
      • 7.3.5.3.Germany market size and forecast, by end user
      • 7.3.5.4.France market size and forecast, by technology
      • 7.3.5.5.France market size and forecast, by indication
      • 7.3.5.6.France market size and forecast, by end user
      • 7.3.5.7.UK market size and forecast, by technology
      • 7.3.5.8.UK market size and forecast, by indication
      • 7.3.5.9.UK market size and forecast, by end user
      • 7.3.5.10.Italy market size and forecast, by technology
      • 7.3.5.11.Italy market size and forecast, by indication
      • 7.3.5.12.Italy market size and forecast, by end user
      • 7.3.5.13.Spain market size and forecast, by technology
      • 7.3.5.14.Spain market size and forecast, by indication
      • 7.3.5.15.Spain market size and forecast, by end user
      • 7.3.5.16.Rest of Europe market size and forecast, by technology
      • 7.3.5.17.Rest of Europe market size and forecast, by indication
      • 7.3.5.18.Rest of Europe market size and forecast, by end user
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends, growth factors, and opportunities
    • 7.4.2.Market size and forecast, by country
    • 7.4.3.Market size and forecast, by technology
    • 7.4.4.Market size and forecast, by indication
    • 7.4.5.Market size and forecast, by end user
      • 7.4.5.1.Japan market size and forecast, by technology
      • 7.4.5.2.Japan market size and forecast, by indication
      • 7.4.5.3.Japan market size and forecast, by end user
      • 7.4.5.4.China market size and forecast, by technology
      • 7.4.5.5.China market size and forecast, by indication
      • 7.4.5.6.China market size and forecast, by end user
      • 7.4.5.7.India market size and forecast, by technology
      • 7.4.5.8.India market size and forecast, by indication
      • 7.4.5.9.India market size and forecast, by end user
      • 7.4.5.10.Australia market size and forecast, by technology
      • 7.4.5.11.Australia market size and forecast, by indication
      • 7.4.5.12.Australia market size and forecast, by end user
      • 7.4.5.13.Rest of Asia-Pacific market size and forecast, by technology
      • 7.4.5.14.Rest of Asia-Pacific market size and forecast, by indication
      • 7.4.5.15.Rest of Asia-Pacific market size and forecast, by end user
  • 7.5.LAMEA
    • 7.5.1.Key market trends, growth factors, and opportunities
    • 7.5.2.Market size and forecast, by country
    • 7.5.3.Market size and forecast, by technology
    • 7.5.4.Market size and forecast, by indication
    • 7.5.5.Market size and forecast, by end user
      • 7.5.5.1.Brazil market size and forecast, by technology
      • 7.5.5.2.Brazil market size and forecast, by indication
      • 7.5.5.3.Brazil market size and forecast, by end user
      • 7.5.5.4.Saudi Arabia market size and forecast, by technology
      • 7.5.5.5.Saudi Arabia market size and forecast, by indication
      • 7.5.5.6.Saudi Arabia market size and forecast, by end user
      • 7.5.5.7.South Africa market size and forecast, by technology
      • 7.5.5.8.South Africa market size and forecast, by indication
      • 7.5.5.9.South Africa market size and forecast, by end user
      • 7.5.5.10.Rest of LAMEA market size and forecast, by technology
      • 7.5.5.11.Rest of LAMEA market size and forecast, by indication
      • 7.5.5.12.Rest of LAMEA market size and forecast, by end user

CHAPTER 8:COMPANY PROFILES

  • 8.1.AstraZeneca plc.
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Product portfolio
    • 8.1.4.Business performance
  • 8.2.CSL Limited
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Product portfolio
    • 8.2.5.Business performance
  • 8.3.Emergent BioSolutions Inc.
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product portfolio
    • 8.3.5.Business performance
    • 8.3.1.Key strategic moves and developments
  • 8.4.GlaxoSmithKline plc.
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
    • 8.4.5.Business performance
    • 8.4.6.Key strategic moves and developments
  • 8.5.Johnson & Johnson
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
    • 8.5.5.Business performance
    • 8.5.6.Key strategic moves and developments
  • 8.6.MERCK & CO. INC.
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Product portfolio
    • 8.6.5.Business performance
    • 8.6.6.Key strategic moves and developments
  • 8.7.NOVAVAX, INC.
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
  • 8.8.PFIZER INC.
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
    • 8.8.6.Key strategic moves and developments
  • 8.9.Sanofi S.A.
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance
    • 8.9.6.Key strategic moves and developments
  • 8.10.SERUM INSTITUTE OF INDIA PVT. LTD
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio

LIST OF TABLES

  • TABLE 01.GLOBAL VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 02.RECOMBINANT & CONJUGATE VACCINE MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 03.INACTIVATED VACCINE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 04.LIVE ATTENUATED VACCINE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 05.TOXOID VACCINE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 06.VACCINE MARKET FOR OTHER VACCINES, BY REGION, 2019-2027 ($MILLION)
  • TABLE 07.GLOBAL VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 08.VACCINE MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 09.VACCINE MARKET FOR INFLUENZA, BY REGION, 2019-2027 ($MILLION)
  • TABLE 10.VACCINE MARKET FOR HUMAN PAPILLOMA VIRUS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 11.VACCINE MARKET FOR MENINGOCOCCAL DISEASE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 12.VACCINE MARKET FOR ROTAVIRUS DISEASE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 13.VACCINE MARKET FOR VARICELLA, MEASLES, MUMPS, AND RUBELLA (MMR), BY REGION, 2019-2027 ($MILLION)
  • TABLE 14.VACCINE MARKET FOR DIPHTHERIA, PERTUSSIS, & TETANUS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 15.VACCINE MARKET FOR POLIO, BY REGION, 2019-2027 ($MILLION)
  • TABLE 16.VACCINE MARKET FOR HEPATITIS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 17.VACCINE MARKET FOROTHER INDICATION, BY REGION, 2019-2027 ($MILLION)
  • TABLE 18.GLOBAL VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 19.VACCINE MARKET FOR PEDIATRIC, BY REGION, 2019-2027 ($MILLION)
  • TABLE 20.VACCINE MARKET FOR ADULTS VACCINES, BY REGION, 2019-2027 ($MILLION)
  • TABLE 21.VACCINE MARKET FOR TRAVELERS VACCINES, BY REGION, 2019-2027 ($MILLION)
  • TABLE 22.VACCINE MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 23.NORTH AMERICA VACCINE MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 24.NORTH AMERICA VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 25.NORTH AMERICA VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 26.NORTH AMERICA MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 27.U.S. VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 28.U.S. VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 29.U.S. VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 30.MEXICO VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 31.MEXICO VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 32.MEXICO VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 33.CANADA VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 34.CANADA VACCINE MARKET, BY INDICATION , 2019-2027 ($MILLION)
  • TABLE 35.CANADA VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 36.EUROPE VACCINE MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 37.EUROPE VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 38.EUROPE VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 39.EUROPE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 40.GERMANY VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 41.GERMANY VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 42.GERMANY VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 43.FRANCE VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 44.FRANCE VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 45.FRANCE VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 46.UK VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 47.UK VACCINE MARKET, BY INDICATION , 2019-2027 ($MILLION)
  • TABLE 48.UK VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 49.ITALY VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 50.ITALY VACCINE MARKET, BY INDICATION , 2019-2027 ($MILLION)
  • TABLE 51.ITALY VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 52.SPAIN VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 53.SPAIN VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 54.SPAIN VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 55.REST OF EUROPE VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 56.REST OF EUROPE VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 57.REST OF EUROPE VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 58.ASIA-PACIFIC VACCINE MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 59.ASIA-PACIFIC VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 60.ASIA-PACIFIC VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 61.ASIA-PACIFIC MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 62.JAPAN VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 63.JAPAN VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 64.JAPAN VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 65.CHINA VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 66.CHINA VACCINE MARKET, BY INDICATION , 2019-2027 ($MILLION)
  • TABLE 67.CHINA VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 68.INDIA VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 69.INDIA VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 70.INDIA VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 71.AUSTRALIA VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 72.AUSTRALIA VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 73.AUSTRALIA VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 74.REST OF ASIA-PACIFIC VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 75.REST OF ASIA-PACIFIC VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 76.REST OF ASIA-PACIFIC VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 77.LAMEA VACCINE MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 78.LAMEA VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 79.LAMEA VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 80.LAMEA MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 81.BRAZIL VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 82.BRAZIL VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 83.BRAZIL VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 84.SAUDI ARABIA VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 85.SAUDI ARABIA VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 86.SAUDI ARABIA VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 87.SOUTH AFRICA VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 88.SOUTH AFRICA VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 89.SOUTH AFRICA VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 90.REST OF LAMEA VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 91.REST OF LAMEA VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 92.REST OF LAMEA VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 93.ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 94.ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 95.CSL: COMPANY SNAPSHOT
  • TABLE 96.CSL: OPERATING SEGMENTS
  • TABLE 97.CSL: PRODUCT PORTFOLIO
  • TABLE 98.EMERGENT SOLUTIONS: COMPANY SNAPSHOT
  • TABLE 99.EMERGENT SOLUTIONS: OPERATING SEGMENTS
  • TABLE 100.EMERGENT SOLUTIONS: PRODUCT PORTFOLIO
  • TABLE 101.GSK: COMPANY SNAPSHOT
  • TABLE 102.GSK: OPERATING SEGMENTS
  • TABLE 103.GSK: PRODUCT PORTFOLIO
  • TABLE 104.J&J: COMPANY SNAPSHOT
  • TABLE 105.J&J: OPERATING SEGMENTS
  • TABLE 106.J&J: PRODUCT PORTFOLIO
  • TABLE 107.MERCK: COMPANY SNAPSHOT
  • TABLE 108.MERCK: OPERATING SEGMENTS
  • TABLE 109.MERCK: PRODUCT PORTFOLIO
  • TABLE 110.NOVAVAX: COMPANY SNAPSHOT
  • TABLE 111.NOVAVAX: PRODUCT PORTFOLIO:
  • TABLE 112.PFIZER: COMPANY SNAPSHOT
  • TABLE 113.PFIZER: OPERATING SEGMENTS
  • TABLE 114.PFIZER: PRODUCT PORTFOLIO
  • TABLE 115.SANOFI: COMPANY SNAPSHOT
  • TABLE 116.SANOFI S.A.: OPERATING SEGMENTS
  • TABLE 117.SANOFI S.A.: PRODUCT PORTFOLIO
  • TABLE 118.SERUM INSTITUTE: COMPANY SNAPSHOT
  • TABLE 119.SERUM INSTITUTE: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.VACCINE MARKETSEGMENTATION
  • FIGURE 02.TOP WINNING STRATEGIES, BY DEVELOPMENTS, 2018-2020*
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2020*
  • FIGURE 04.TOP WINNING STRATEGIES: COMPANY , 2018-2020
  • FIGURE 05.TOP PLAYER POSITIONING, 2019
  • FIGURE 06.TOP INVESTMENT POCKETS
  • FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIER
  • FIGURE 08.MODERATEBARGAINING POWER OF BUYERS
  • FIGURE 09.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 10.HIGH INTENSITY OF RIVALRY
  • FIGURE 11.HIGH THREAT OF NEW ENTRANT
  • FIGURE 12.IMPACT ANALYSIS, VACCINE MARKET
  • FIGURE 14.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR RECOMBINANT & CONJUGATE VACCINES, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 16.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR INACTIVATED VACCINE, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 18.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 19.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR TOXOID, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 20.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 21.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 22.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR INFLUENZA, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 23.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR HUMAN PAPILLOMA VIRUS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 24.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 25.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR ROTAVIRUS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 26.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR VARICELLA, MEASLES, MUMPS, & RUBELLA DISEASE, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 27.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR DIPHTHERIA, PERTUSSIS, & TETANUS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 28.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR POLIO, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 29.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR HEPATITIS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 30.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 31.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR PEDIATRIC, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 32.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR ADULT, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 33.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR TRAVELERS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 34.ASTRAZENECA: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 35.ASTRAZENECA: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 36.CSL: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 37.CSL REVENUE SHARE BY SEGMENTS, 2019 (%)
  • FIGURE 38.CSL LIMITED: REVENUE SHARE BY REGIONS, 2019 (%)
  • FIGURE 39.EMERGENT SOLUTIONS: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 40.EMERGENT SOLUTIONS: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 41.EMERGENT SOLUTIONS: REVENUE SHARE BY REGION, 2019(%)
  • FIGURE 42.GSK: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 43.GSK: REVENUE SHARE BY SEGMENT, 2019(%)
  • FIGURE 44.GSK: REVENUE SHARE BY REGION, 2019(%)
  • FIGURE 45.J&J: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 46.J&J: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 47.J&J: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 48.MERCK: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 49.MERCK: REVENUE SHARE BY SEGMENTS, 2019 (%)
  • FIGURE 50.MERCK: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 51.NOVAVAX: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 52.PFIZER: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 53.PFIZER: REVENUE SHARE BY SEGMENTS, 2019 (%)
  • FIGURE 54.PFIZER: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 55.SANOFI S.A.: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 56.SANOFI: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 57.SANOFI: REVENUE SHARE BY REGION, 2019(%)